Indeed, clinical trials using FGF21 analogs in individuals with obesity did not show any weight‐reducing effects although lipid profiles, glucose homeostasis, and whole‐body insulin sensitivity were improved.213, 214. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.